

Supplementary Table 1. Details of platinum sensitivity and best response to olaparib and post-PARPi chemotherapy of the six patients whose tumor samples were analyzed by massively parallel sequencing. (NE: not evaluable)

Patient	Pre-olaparib platinum sensitivity	Best olaparib response		Platinum to post-PARPi chemotherapy interval (weeks)	Post-olaparib chemotherapy	Best response to post-olaparib chemotherapy	
		RECIST	CA125			RECIST	CA125
1	Resistant	SD	CR	100	Carboplatin, PLD	PD	PD
2	Resistant	SD	SD	58	Paclitaxel	SD	PR
3	Sensitive	PR	CR	188	Carboplatin, PLD	PR	PR
4	Sensitive	SD	NE	144	Carboplatin, PLD	SD	NE
5	Sensitive	CR	CR	224	Carboplatin	PR	NE
6	Partially sensitive	SD	PR	60	Carboplatin, Paclitaxel	PR	PR